134 related articles for article (PubMed ID: 24066096)
1. Duration of anti-tuberculosis therapy and timing of antiretroviral therapy initiation: association with mortality in HIV-related tuberculosis.
Cortes CP; Wehbe FH; McGowan CC; Shepherd BE; Duda SN; Jenkins CA; Gonzalez E; Carriquiry G; Schechter M; Padgett D; Cesar C; Madero JS; Pape JW; Masys DR; Sterling TR;
PLoS One; 2013; 8(9):e74057. PubMed ID: 24066096
[TBL] [Abstract][Full Text] [Related]
2. Initiation of antiretroviral therapy in HIV-infected tuberculosis patients in rural Kenya: an observational study.
Stockdale AJ; Nkuranga J; Török ME; Faragher B; Lalloo DG
Trop Med Int Health; 2013 Jul; 18(7):907-14. PubMed ID: 23590229
[TBL] [Abstract][Full Text] [Related]
3. The shift in tuberculosis timing among people living with HIV in the course of antiretroviral therapy scale-up in Malawi.
Tweya H; Feldacker C; Mpunga J; Kanyerere H; Heller T; Ganesh P; Nkosi D; Kalulu M; Sinkala G; Satumba T; Phiri S
J Int AIDS Soc; 2019 Apr; 22(4):e25240. PubMed ID: 31038836
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of the interval between the initiation of antiretroviral therapy and the initiation of anti-tuberculosis treatment in HIV/tuberculosis-coinfected patients: results from the TREAT Asia HIV Observational Database.
Han SH; Zhou J; Lee MP; Zhao H; Chen YM; Kumarasamy N; Pujari S; Lee C; Omar SF; Ditangco R; Phanuphak N; Kiertiburanakul S; Chaiwarith R; Merati TP; Yunihastuti E; Tanuma J; Saphonn V; Sohn AH; Choi JY;
HIV Med; 2014 Feb; 15(2):77-85. PubMed ID: 23980589
[TBL] [Abstract][Full Text] [Related]
5. Treatment response and mortality among patients starting antiretroviral therapy with and without Kaposi sarcoma: a cohort study.
Maskew M; Fox MP; van Cutsem G; Chu K; Macphail P; Boulle A; Egger M; Africa FI
PLoS One; 2013; 8(6):e64392. PubMed ID: 23755122
[TBL] [Abstract][Full Text] [Related]
6. The Effect of Early Initiation of Antiretroviral Therapy in TB/HIV-Coinfected Patients: A Systematic Review and Meta-Analysis.
Abay SM; Deribe K; Reda AA; Biadgilign S; Datiko D; Assefa T; Todd M; Deribew A
J Int Assoc Provid AIDS Care; 2015; 14(6):560-70. PubMed ID: 26289343
[TBL] [Abstract][Full Text] [Related]
7. Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults.
Siegfried N; Uthman OA; Rutherford GW
Cochrane Database Syst Rev; 2010 Mar; 2010(3):CD008272. PubMed ID: 20238364
[TBL] [Abstract][Full Text] [Related]
8. Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy.
Manosuthi W; Chottanapand S; Thongyen S; Chaovavanich A; Sungkanuparph S
J Acquir Immune Defic Syndr; 2006 Sep; 43(1):42-6. PubMed ID: 16885778
[TBL] [Abstract][Full Text] [Related]
9. Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: results from the TIME study.
Manosuthi W; Mankatitham W; Lueangniyomkul A; Thongyen S; Likanonsakul S; Suwanvattana P; Thawornwan U; Suntisuklappon B; Nilkamhang S; Sungkanuparph S;
J Acquir Immune Defic Syndr; 2012 Aug; 60(4):377-83. PubMed ID: 22592586
[TBL] [Abstract][Full Text] [Related]
10. Timing of antiretroviral therapy in Cambodian hospital after diagnosis of tuberculosis: impact of revised WHO guidelines.
Choun K; Pe R; Thai S; Lorent N; Lynen L; van Griensven J
Bull World Health Organ; 2013 Mar; 91(3):195-206. PubMed ID: 23476092
[TBL] [Abstract][Full Text] [Related]
11. Antiretroviral therapy improves survival among TB-HIV co-infected patients who have CD4+ T-cell count above 350cells/mm
Mutembo S; Mutanga JN; Musokotwane K; Alisheke L; Whalen CC
BMC Infect Dis; 2016 Oct; 16(1):572. PubMed ID: 27751168
[TBL] [Abstract][Full Text] [Related]
12. Tuberculosis-related mortality in people living with HIV in Europe and Latin America: an international cohort study.
Podlekareva DN; Efsen AM; Schultze A; Post FA; Skrahina AM; Panteleev A; Furrer H; Miller RF; Losso MH; Toibaro J; Miro JM; Vassilenko A; Girardi E; Bruyand M; Obel N; Lundgren JD; Mocroft A; Kirk O;
Lancet HIV; 2016 Mar; 3(3):e120-31. PubMed ID: 26939735
[TBL] [Abstract][Full Text] [Related]
13. Clinical deterioration during antituberculosis treatment in Africa: incidence, causes and risk factors.
Pepper DJ; Marais S; Wilkinson RJ; Bhaijee F; Maartens G; McIlleron H; De Azevedo V; Cox H; McDermid C; Sokhela S; Patel J; Meintjes G
BMC Infect Dis; 2010 Mar; 10():83. PubMed ID: 20353569
[TBL] [Abstract][Full Text] [Related]
14. Active tuberculosis is associated with worse clinical outcomes in HIV-infected African patients on antiretroviral therapy.
Siika AM; Yiannoutsos CT; Wools-Kaloustian KK; Musick BS; Mwangi AW; Diero LO; Kimaiyo SN; Tierney WM; Carter JE
PLoS One; 2013; 8(1):e53022. PubMed ID: 23301015
[TBL] [Abstract][Full Text] [Related]
15. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata.
Palella FJ; Deloria-Knoll M; Chmiel JS; Moorman AC; Wood KC; Greenberg AE; Holmberg SD;
Ann Intern Med; 2003 Apr; 138(8):620-6. PubMed ID: 12693883
[TBL] [Abstract][Full Text] [Related]
16. Causes and determinants of mortality in HIV-infected adults with tuberculosis: an analysis from the CAMELIA ANRS 1295-CIPRA KH001 randomized trial.
Marcy O; Laureillard D; Madec Y; Chan S; Mayaud C; Borand L; Prak N; Kim C; Lak KK; Hak C; Dim B; Sok T; Delfraissy JF; Goldfeld AE; Blanc FX;
Clin Infect Dis; 2014 Aug; 59(3):435-45. PubMed ID: 24759827
[TBL] [Abstract][Full Text] [Related]
17. HIV-related tuberculosis: mortality risk in persons without vs. with culture-confirmed disease.
Crabtree-Ramírez B; Jenkins C; Jayathilake K; Carriquiry G; Veloso V; Padgett D; Gotuzzo E; Cortes C; Mejia F; McGowan CC; Duda S; Shepherd BE; Sterling TR
Int J Tuberc Lung Dis; 2019 Mar; 23(3):306-314. PubMed ID: 30871661
[TBL] [Abstract][Full Text] [Related]
18. Tuberculosis treatment intermittency in the continuation phase and mortality in HIV-positive persons receiving antiretroviral therapy.
Crabtree-Ramirez B; Jenkins CA; Shepherd BE; Jayathilake K; Veloso VG; Carriquiry G; Gotuzzo E; Cortes CP; Padgett D; McGowan C; Sierra-Madero J; Koenig S; Pape JW; Sterling TR;
BMC Infect Dis; 2022 Apr; 22(1):341. PubMed ID: 35382770
[TBL] [Abstract][Full Text] [Related]
19. Antiretroviral therapy initiation during tuberculosis treatment and HIV-RNA and CD4 T-lymphocyte responses.
Takuva S; Westreich D; Menezes CN; McNamara L; Sanne I; Page-Shipp L; Maskew M
Int J Tuberc Lung Dis; 2012 Oct; 16(10):1358-64. PubMed ID: 22863288
[TBL] [Abstract][Full Text] [Related]
20. Tuberculosis incidence rate and risk factors among HIV-infected adults with access to antiretroviral therapy.
Liu E; Makubi A; Drain P; Spiegelman D; Sando D; Li N; Chalamilla G; Sudfeld CR; Hertzmark E; Fawzi WW
AIDS; 2015 Jul; 29(11):1391-9. PubMed ID: 26091295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
